Abstract:Introduction Influenza A virus (IAV) infection predisposes to subsequent bacterial superinfection in the lungs. Streptococcus pneumoniae (Sp) is the main bacteria involved in this co-infection process and promotes a greater pneumonia severity. Because alveolar macrophages (AM) are critical in maintaining alveoli homeostasis, we suspect an IAV-induced dysfunction of the lung granulocyte macrophages stimulating colony factor (GM-CSF) production that drives the AM function. The aim of the study is (i) to examine if a defective GM-CSF signaling could be evidenced during IAV infection and, (ii) to assess whether administration of GM-CSF protects mice from Sp superinfection. Methods We compared GM-CSF production in bronchoalveolar lavage (BAL) from IAV infected mice and human. c57BL/6J mice were infected by a mild inoculum of influenza A virus (IAV, H3N2, 10 PFU) by intranasal route (IN). GM-CSF concentration in human BAL was obtained from patients with PCR-confirmed influenza infection and a BAL performed within the four firth days of ICU admission. Next, we performed a bioinformatic analysis based on publicly available AM transcriptomic datasets collected in IAV-infected mice and Csf2 (colony stimulating factor 2)-/- mice. From Csf2-/- mice, we defined genes that are altered when the GM-CSF instruction is defective. Using the transcriptome dataset of AM from IAV-infected mice (and control) we assessed whether AM presented a GM-CSF defective signature. Finally, IAV-infected mice were treated by GM-CSF (IN, 10 μg/mouse) at day 0, 2- and 4-days post-infection (dpi), and superinfected at dpi 7 by Sp (IN, SP1 strain). We monitored weight, survival and AM count. Results A lung GM-CSF production was observed in BAL of IAV-infected patient, but not in mice. In AM collected from IAV-infected mice, nearly all the genes whose expression reflect the lack of GM-CSF instruction were up regulated ( n = 25/28). Moreover, AM count dropped drastically after IAV-infection: AM represented only 35% from baseline AM count in BAL at dpi 7. However, IAV-induced AM depletion was significantly less important in mice treated with GM-CSF (62% from baseline count). Results were similar when studying AM count in BAL or lung homogenate. Finally, GM-CSF administration in IAV-infected mice reduced mortality by 50% of Sp – superinfection (preliminary data). Conclusion It is likely that there are alterations of the GM-CSF instruction post-IAV infection that prevents efficient AM immune function, as reveal by the murine models. Consistently, GM-CSF administration prevents mAMs depletion and mortality due to bacterial superinfection in IAV-infected mice. These data underline the potential protective role of GM-CSF during influenza infection.

Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome

GM-CSF shields IAV-infected mice from bacterial superinfection

GM-CSF in the Lung Protects Against Lethal Influenza Infection

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies

Evaluation of porcine GM-CSF during PRRSV infection in vitro and in vivo indicating a protective role of GM-CSF related with M1 biased activation in alveolar macrophage during PRRSV infection

Protective Effects of Recombinant Human Granulocyte Macrophage Colony Stimulating Factor on H1N1 Influenza Virus-Induced Pneumonia in Mice.

Local GM-CSF–Dependent Differentiation and Activation of Pulmonary Dendritic Cells and Macrophages Protect against Progressive Cryptococcal Lung Infection in Mice

GM-CSF-mediated epithelial-immune cell crosstalk orchestrates pulmonary immunity to

Effect of intranasal administration of Granulocyte-Macrophage Colony-Stimulating Factor on pulmonary Cryptococcus gattii infection

GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches

Dual GM-CSF and IL-17A expressing CD8+ T cells mediate vaccine-immunity, but not immunopathology, against lethal fungal pneumonia in CD4+ T-cell deficient hosts

Clinical study of rhGM-CSF for the treatment of pulmonary exogenous acute respiratory distress syndrome by modulating alveolar macrophage subtypes: A randomized controlled trial

G‐CSFR antagonism reduces mucosal injury and airways fibrosis in a virus‐dependent model of severe asthma

GM-CSF Targeted Immunomodulation Affects Host Response to M. Tuberculosis Infection

Alveolar epithelial cells orchestrate DC function in murine viral pneumonia

Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19

Effects of granulocyte-macrophage colony stimulating factor gene encoded vaccinia virus vector on murine pulmonary metastatic melanoma

Aberrant pathogenic GM-CSF<sup>+</sup> T cells and inflammatory CD14<sup>+</sup>CD16<sup>+</sup> monocytes in severe pulmonary syndrome patients of a new coronavirus

Neutrophils drive pulmonary vascular leakage in MHV-1 infection of susceptible A/J mice

TL1A and IL-18 synergy promotes GM-CSF-dependent thymic granulopoiesis in mice

[GM-CSF and G-CSF: cytokines in clinical application]